

# BC Cancer Protocol Summary for the Treatment of Multiple Myeloma Using Bortezomib, Dexamethasone With or Without Cyclophosphamide as Induction Pre-Stem Cell Transplant

**Protocol Code**

*MYBORPRE*

**Tumour Group**

*Lymphoma, Leukemia/BMT*

**Contact Physician**

*Dr. Kevin Song*

## ELIGIBILITY:

- Previously untreated multiple myeloma or amyloid light (AL) chain amyloidosis patients who are ELIGIBLE for autologous stem cell transplant (ASCT), or
- Patients with relapsed multiple myeloma who may go on to receive a second stem cell transplant

## Notes:

- A referral to the Leukemia/BMT Program of BC must be made for consideration of transplant at the start of the first cycle.
- The addition of cyclophosphamide will increase response and should be used when possible
- The last bortezomib and cyclophosphamide dose should be given at least 14 days prior to stem cell collection.
- Platelet count less than  $30 \times 10^9/L$  may require transfusion support
- If absolute neutrophil count (ANC) less than  $0.5 \times 10^9/L$  may require giving filgrastim

## EXCLUSIONS:

- none

## TESTS:

- Baseline: CBC, differential, platelets, creatinine, serum bilirubin, ALT
- Baseline (required, but results do not have to be available to proceed with first treatment; results must be checked before proceeding with cycle 2): calcium, serum protein electrophoresis ***and/or*** serum free light chain levels, beta-2-microglobulin, HBsAg, HBcoreAntibody, if not previously documented
- Before day 1 (**for bortezomib and cyclophosphamide if using**): CBC, differential, platelets, creatinine, ALT, serum bilirubin
- Before day 1 (required, but results do not have to be available to proceed with treatment) calcium, serum protein electrophoresis ***and/or*** serum free light chain levels
- If CBC prior to day 1 show ANC less than  $1.5 \times 10^9/L$  or platelets less than  $100 \times 10^9/L$ , then:
  - Before day 8, 15, 22 (**for bortezomib only, in weekly dosing**): CBC, differential
  - Before day 11 (**for bortezomib only, in twice weekly dosing**): CBC, differential

**PREMEDICATIONS:**

- Routine anti-emetic or anti-diarrheal premedication is not required. These symptoms should be managed symptomatically if they arise.
- Antiviral prophylaxis is recommended prior to initiating bortezomib for patients who have a history of varicella zoster virus (VZV) infection (chicken pox and shingles). Patients should take valACYclovir 500 mg PO daily while taking bortezomib and for 4 weeks after its discontinuation.

**SUPPORTIVE MEDICATIONS:**

If HBsAg or HBcoreAb positive, start lamiVUDine 100 mg PO daily for the duration of chemotherapy and continue for one year from treatment completion for patients who are HBsAg positive and for six months for patients who are HBcoreAb positive.

Oral proton-pump inhibitor or H<sub>2</sub> antagonist for the duration of treatment with dexamethasone or prednisone may be considered

**RECOMMENDED TREATMENT:**

The once weekly bortezomib treatment option is preferred over the twice weekly bortezomib treatment option

Duration of treatment: up to 6 cycles. For further treatment, “Compassionate Access Program” request is required.

**ONCE WEEKLY TREATMENT:** cycle length 28 days

Drug	Dose	BC Cancer Administration Guideline
bortezomib	1.5 mg/m <sup>2</sup> (may start with 1.3 mg/m <sup>2</sup> ) on days 1, 8, 15, 22 of each cycle	SC (abdomen or thigh)*
<b><u>If using:</u></b> cyclophosphamide	300 mg/m <sup>2</sup> /day on days 1, 8, 15, 22**	PO
dexamethasone	Cycle 1 & 2: 40 mg on days 1-4, 9-12, 17-20 Cycle 3 onwards: 40 mg on days 1, 8, 15, 22	PO, in the morning with food

\*Back of the arm can also be considered as a third option, after abdomen or thigh

\*\*Round dose to nearest 25 mg

**TWICE WEEKLY OPTION:** cycle length 21 days

Drug	Dose	BC Cancer Administration Guideline
bortezomib	1.3 mg/m <sup>2</sup> on days 1, 4, 8, 11 of each cycle (+/- one day maintaining at least 72 h between doses)	SC (abdomen or thigh)*
<b><u>If using:</u></b> cyclophosphamide	300 mg/m <sup>2</sup> /day on days 1, 8, 15**	PO
dexamethasone	Cycle 1 and 2: 40 mg on days 1-4, 9-12 Cycle 3 onwards: 40 mg on days 1, 4, 8, 11 (same days as Bortezomib is given)	PO, in the morning with food

\* Back of the arm can also be considered as a third option, after abdomen or thigh

\*\*Round dose to nearest 25 mg

Other Steroid Schedules can be used (but may result in lower efficacy). Dose should be adjusted based upon toxicity and patient tolerance. Some examples included below:

<p>Option A: Oral dexamethasone 20 mg in place of 40mg</p>
<p>Option B: predniSONE may be substituted for patient or physician preference, in a variety of regimens based upon toxicity and patient tolerance (e.g. 100 mg PO on alternate days or 50 mg PO on alternate days)</p>

## DOSE MODIFICATIONS:

### 1. Hematological:

ANC (x10 <sup>9</sup> /L)	Platelets (x10 <sup>9</sup> /L)	Bortezomib Dose
greater than or equal to 0.5	And greater than or equal to 30	100%
less than 0.5	Or less than 30	Consider delay until recovery checking CBC weekly; reduce dose to 1.3 mg/m <sup>2</sup> (for once weekly bortezomib dosing) or 1 mg/m <sup>2</sup> (for twice weekly bortezomib dosing).
reoccurrence of less than 0.5	reoccurrence of less than 30	Consider delay until recovery checking CBC weekly; further reduce dose to 1 mg/m <sup>2</sup> (for once weekly bortezomib dosing) or 0.7 mg/m <sup>2</sup> (for twice weekly bortezomib dosing).

### For Cyclophosphamide (If using) lab on day 1 only

ANC (x10 <sup>9</sup> /L)	Platelets (x10 <sup>9</sup> /L)	Dose (cyclophosphamide)
greater than or equal to 1.0	greater than or equal to 80	100%
less than 1.0	less than 80	Consider delay until recovery checking CBC weekly

## 2. Peripheral Neuropathy:

Severity of Peripheral Neuropathy Signs and Symptoms	Bortezomib Dose
Grade 1 (paresthesia and/or loss of reflexes) without pain or loss of function	100%
Grade 1 with pain or Grade 2 (interfering with function but not with activities of daily living)	Reduce dose to 1.3 mg/m <sup>2</sup> (for once weekly dosing) or 1 mg/m <sup>2</sup> (for twice weekly dosing)
Grade 2 with pain or Grade 3 (interfering with activities of daily living)	Delay until recovery. When resolved, reduce dose to 1 mg/m <sup>2</sup> weekly x 2 doses q 21 days (for once weekly dosing) or 0.7 mg/m <sup>2</sup> weekly x 2 doses q 21 days (for twice weekly dosing)
Grade 4 (permanent sensory loss that interferes with function)	Discontinue treatment

## 3. Hepatic Impairment:

	Bilirubin	ALT or AST	Bortezomib Dose
Mild	less than or equal to 1 x upper limit of normal	greater than the upper limit of normal	100%
	greater than 1 – 1.5 x upper limit of normal	Any	100%
Moderate	greater than 1.5-3 x upper limit of normal	Any	<ul style="list-style-type: none"> <li>▪ Reduce dose to 0.7 mg/m<sup>2</sup> in the first cycle.</li> <li>▪ Consider dose escalation to 1 mg/m<sup>2</sup> <u>or</u> further dose reduction to 0.5 mg/m<sup>2</sup> in subsequent cycles based on patient tolerability.</li> </ul>
Severe	greater than 3 x upper limit of normal	Any	

For Cyclophosphamide, no dose reduction is necessary for hepatic impairment.

#### 4. Renal Failure:

For Bortezomib, no dose reduction is necessary for renal failure. For patients on hemodialysis, give dose after dialysis.

For Cyclophosphamide, dose reduction is necessary for renal failure. For patients on hemodialysis, give dose after dialysis. Physician may consider giving full dose of cyclophosphamide irrespective of renal function if deemed to be of benefit.

Creatinine clearance (mL/min)	Cyclophosphamide Dose
Greater than or equal to 10	100 %
Less than 10	75 %

Calculated creatinine clearance =  $\frac{N \times (140 - \text{Age}) \times \text{weight (kg)}}{\text{Serum Creatinine (micromols/L)}}$

N = 1.04 (Females) and 1.23 (Males)

#### PRECAUTIONS:

**1. Neutropenia:** fever or other evidence of infection must be assessed promptly and treated aggressively.

**2. Need for irradiated blood products:** Patients receiving an autotransplant require irradiated blood products from 7 days prior to collection to 3 months post transplant (6 months if total body irradiation conditioning) to eliminate the risk of potentially life-threatening transfusion-related graft-versus-host-disease. All other myeloma patients do not require irradiated blood products.

**3. Green tea avoidance:** Some of the components in green tea and preparations made from green tea block the activity of bortezomib in in vitro experiments. Green tea or preparations made from green tea should be avoided by patients taking bortezomib.

## 4. Diarrhea

### Diarrhea grading system

Grade 1	Grade 2	Grade 3	Grade 4
Increase of less than 4 stools per day over baseline; mild increase in ostomy output compared to baseline	Increase of 4 – 6 stools per day over baseline; IV fluids indicated for less than 24hrs; moderate increase in ostomy output compared to baseline; not interfering with activities of daily living	Increase of greater than 7 stools per day over baseline; incontinence; IV fluids for greater than 24 hrs; hospitalization; severe increase in ostomy output compared to baseline; interfering with activities of daily living	Life-threatening consequences (e.g., hemodynamic collapse)
Treatment of Diarrhea during cycle			
At first loose stool:	Start loperamide 2 mg po q 2 h while awake and q 4 h while sleeping. Continue around the clock until 12 h diarrhea free	<ul style="list-style-type: none"> <li>• If diarrhea free greater than 12 h, stop loperamide. If new episode, retreat with loperamide.</li> <li>• If grade 3 diarrhea or diarrhea accompanied by mucus or dehydration, hold doses of Bortezomib (if applicable) and hydrate.</li> </ul>	

Diarrhea management: Next Cycle Dosing	
Delay next cycle until diarrhea has resolved (less than 2 watery bowel movements / day)	
Severity of diarrhea with last cycle:	Bortezomib dose this cycle
less than or equal to grade 2	no change from previous cycle
greater than or equal to grade 3 or associated with mucus or dehydration	Reduce dose to 80% of that used in the last course or consider once a week dosing. (if two dose reductions have already occurred further treatment with Bortezomib must be individualised and should only continue if a clearly useful clinical response in the myeloma has occurred)

**5. Live vaccines:** Patients with any history of lymphoid cancers including myeloma should not be given live vaccines.

**6. Hepatitis B Reactivation:** All lymphoma/myeloma patients should be tested for both HBsAg and HBcoreAntibody. If either test is positive, such patients should be treated with lamiVUDine during chemotherapy and continue for one year from treatment completion for patients who are HBsAg positive and for six months for patients who are HBcoreAb positive. Such patients should also be monitored with frequent liver function tests and hepatitis B virus DNA at least every two months. If the hepatitis B virus DNA level rises during this monitoring, management should be reviewed with an appropriate specialist with experience managing hepatitis and consideration given to halting chemotherapy.

**7. H. zoster (shingles) prophylaxis:** Antiviral prophylaxis is recommended prior to initiating bortezomib for patients who are VZV seropositive. Patients should take valACYclovir 500 mg PO daily while taking bortezomib and for 4 weeks after its discontinuation. Of note, VZV serology is often not reliable, even in patients previously exposed. Most clinicians choose to prescribe valACYclovir without testing for VZV serology.

**8. Platelet counts:** If the patient's platelet count on day 1 is less than  $100 \times 10^9/L$ , the platelet count should be checked on day 11 and that day's dose should be omitted if the platelet count is less than  $30 \times 10^9/L$  on day 11.

**9. Peripheral Neuropathy:** occurs in 36–37% of patients receiving IV bortezomib with 8–14% resulting in grade 3–4 severity of symptoms. This is a common and often dose limiting side effect. Administration of bortezomib via the subcutaneous route instead of IV push significantly reduces the occurrence of peripheral neuropathy.

**Call Dr. Kevin Song (Leukemia/BMT) or Dr Laurie Sehn (Lymphoma) or tumour group delegate with any problems or questions regarding this treatment program. (Leukemia/BMT at (604) 875-4863 or after hours (604) 875-4111; Lymphoma at (604) 877-6000 or 1-800-663-3333)**

#### References:

1. Richardson PG, Barlogie B, Berenson J, et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. *N Engl J Med* 2003;348:2609-17.
2. Hideshima T, Mitsiades C, Akiyama M, et al. Molecular mechanisms mediating antimyeloma activity of proteasome inhibitor PS-341. *Blood* 2003;101:1530-4.
3. Richardson PG, Sonneveld P, Schuster MW, et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. *N Engl J Med* 2005;352:2487-98.
4. Chanan-Khan AA, Kaufman JL, Mehta, J, et al. Activity and safety of bortezomib in multiple myeloma patients with advanced renal failure: a multicenter retrospective study. *Blood* 2007;109:2604-6.
5. Reece DE, Rodriguez GP, Chen C, et al. Phase I - II trial of Bortezomib Plus Oral Cyclophosphamide and Prednisone in Relapsed and Refractory Multiple Myeloma. *J Clin Oncol* 2008;26:29:4777-83
6. Reeder CB, Reece DE, Kukreti V, et al. Cyclophosphamide, bortezomib and dexamethasone induction for newly diagnosed multiple myeloma: high response rates in a phase II clinical trial. *Leukemia* 2009; 23:1337-41.
7. Reeder CB, Reece DE, Kukreti V, et al. Once- versus twice-weekly bortezomib induction therapy with CyCorD in newly diagnosed multiple myeloma. *Blood* 2010; 115:16:3416
8. Moreau P, Coiteux V, Hulin C, et al. Prospective Comparison of subcutaneous versus intravenous administration of bortezomib in patients with multiple myeloma. *Haematologica* 2008;93:1908-11.
9. Moreau P, Pylypenko H, Grosicki S, et al. Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomized, phase 3, non-inferiority study. *Lancet Oncol*. 2011;12(5):431-40.
10. Sonneveld P, Schmidt-Wolf I, van der Holt B *et al*. HOVON-65/GMMG-HD4 Randomized phase III trial comparing bortezomib, doxorubicin, dexamethasone (PAD) vs VAD followed by high-dose melphalan (HDM) and maintenance

- with bortezomib or thalidomide in patients with newly diagnosed multiple myeloma (MM). *ASH Annual Meeting Abstracts* 2010;116(21):40-.
11. Harousseau JL, Attal M, Avet-Loiseau H et al. Bortezomib plus dexamethasone is superior to vincristine plus doxorubicin plus dexamethasone as induction treatment prior to autologous stem-cell transplantation in newly diagnosed multiple myeloma: results of the IFM 2005-01 phase III trial. *J Clin Oncol* 2010;28(30):4621-9.
  12. Cavo M, Tacchetti P, Patriarca F et al. Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study. *Lancet* 2010;376:2075-85.
  13. Stewart AK, Richardson PG, San-Miguel JF. How I treat multiple myeloma in younger patients. *Blood* 2009;114:5436-43.
  14. Venner CP, Gillmore JD, Sachchithanatham S, et al. A matched comparison of cyclophosphamide, bortezomib and dexamethasone versus risk-adapted cyclophosphamide, thalidomide and dexamethasone in AL amyloidosis. *Leukemia* 2014;28(12):2304-10.
  15. Reece DE, Hegenbart U, Sanchorawala V, et al. Long-term follow-up from a phase 1/2 study of single-agent bortezomib in relapsed systemic AL amyloidosis. *Blood* 2014;124(16):2498-506.
  16. Dimopoulos M, Sonneveld P, Leung N et al. International Myeloma Working Group Recommendations for the diagnosis and Management of Myeloma-Related Renal Impairment. *J Clin Oncol* 2016; 34 (13): 1544-57